Format

Send to

Choose Destination
Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S11-5.

Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients.

Author information

1
Division of Nephrology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. deh5@po.cwru.edu

Abstract

African-American renal transplant recipients have higher rates of acute allograft rejection and lower rates of allograft survival compared with Caucasian patients, and these differences have not been eliminated by a new generation of potent immunosuppressive drugs. In particular, African-Americans tend to exhibit higher rejection rates after withdrawal of corticosteroid therapy. Based on promising early results using the combination of sirolimus and low-dose tacrolimus in liver, kidney-pancreas, and islet-cell transplant recipients, our center is conducting a pilot study of this immunosuppression regimen in African-American patients. As of April 2001, there has been only 1 acute rejection episode (2.8%) in this cohort. Long-term follow-up of these patients will be necessary to assess the benefits and risks of this regimen.

PMID:
11583939
DOI:
10.1053/ajkd.2001.27505
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center